AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

HealthBeacon SHA

Legal Proceedings Report Jan 31, 2024

1975_rns_2024-01-31_2296af0a-ea7a-4109-92f7-379cf6f15df4.html

Legal Proceedings Report

Open in Viewer

Opens in native device viewer

National Storage Mechanism | Additional information

RNS Number : 5731B

HealthBeacon PLC

31 January 2024

Update on Examinership Process

Dublin, 31 January 2024.  The board of HealthBeacon plc ("HealthBeacon" or the "Company) announces an update on the Examinership process the Company is currently going through.

Further to the announcement made on 29 January 2024, a hearing before the High Court will take place at 11 am on 1 February 2024 seeking the sanction from the High Court of the Scheme of Arrangement which had been formulated by the Examiner to enable the Company to survive as a going concern.

-Ends-

Enquiries: [email protected]
HealthBeacon:

Rebecca Shanahan

Lar Malone
Goodbody (Euronext Listing Sponsor and Broker):

Finbarr Griffin
+353 (1) 667 0420
Drury (Public Relations):
Cathal Barry +353 (0) 87 227 9281
Gavin McLoughlin +353 (0) 86 035 3749

About HealthBeacon

Headquartered in Dublin, HealthBeacon is an Irish digital therapeutics company that develops smart tools for managing medications for patients in the home. The HealthBeacon Injection Care Management System tracks adherence and persistence with medication schedules through the provision of medication management reminders, safe and sustainable sharps disposal devices, educational tools, and artificial intelligence (AI) driven data analytics. Peer reviewed evidence supports a 19% improvement in therapy persistence by patients and up to 26% improvement in adherence to therapy, which improves clinical outcomes and significantly improves efficiency in health systems. The Company has expanded its offering to growth management with the launch of its integrated Smart Scale and oral adherence with the launch of HB Wave which integrates with its existing technology. The Company operates across Europe, North America and the United Kingdom. The Company's mission is to become the world's leading digital therapeutics platform for patients managing medications in the home.

End

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

ISEBSGDBGGXDGSB

Talk to a Data Expert

Have a question? We'll get back to you promptly.